Xtalpi Inc. has announced regulatory clearances in Australia and Taiwan for phase I trials of PEP-08, a next-generation PRMT5 inhibitor candidate developed under its AI drug discovery collaboration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback